Breaking Finance News

Zacks Investment Research downgraded Mazor Robotics Ltd – ADR (NASDAQ:MZOR) to Sell in a statement released earlier today.

Zacks Investment Research has downgraded Mazor Robotics Ltd – ADR (NASDAQ:MZOR) to Sell in a statement released on 10/14/2016.

On Tuesday October 11, 2016, B. Riley reported on Mazor Robotics Ltd – ADR (NASDAQ:MZOR) raised the target price from $0.00 to $25.00. At the time, this indicated a possible downside of -0.03%.

Yesterday Mazor Robotics Ltd – ADR (NASDAQ:MZOR) traded -1.29% lower at $23.75. The company’s 50-day moving average is $23.40 and its two hundred day average is $18.37. With the last close up 29.30% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Volume of trade was down over the average, with 127,331 shares of MZOR changing hands under the typical 159,845

See Chart Below

Mazor Robotics Ltd - ADR (NASDAQ:MZOR)

Mazor Robotics Ltd – ADR has a with a one year low of $8.31 and a one year high of $26.55 MZOR’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 5 brokers have issued a report on the stock. The consensus target price is $17.10 with two brokerages rating the company a strong buy, two brokerages rating the company a buy, two brokerages rating the company a hold, zero brokerages rating the company a underperform, and lastly 0 brokerages rating the stock a sell.

Brief Synopsis On Mazor Robotics Ltd – ADR (NASDAQ:MZOR)

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *